5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy
Open accessThe DOI matches its Crossref record; 170 of the 180 references it cites were found in a registry or an index; 75 of the 205 sources its claims cite were checked for support.
Abstract
5-Aminolevulinic acid (ALA) is a naturally occurring amino acid synthesized in all nucleated mammalian cells. As a porphyrin precursor, ALA is metabolized in the heme biosynthetic pathway to produce protoporphyrin IX (PpIX), a fluorophore and photosensitizing agent. ALA administered exogenously bypasses the rate-limit step in the pathway, resulting in PpIX accumulation in tumor tissues. Such tumor-selective PpIX disposition following ALA administration has been exploited for tumor fluorescence diagnosis and photodynamic therapy (PDT) with much success. Five ALA-based drugs have now received worldwide approval and are being used for managing very common human (pre)cancerous diseases such as actinic keratosis and basal cell carcinoma or guiding the surgery of bladder cancer and high-grade gliomas, making it the most successful drug discovery and development endeavor in PDT and photodiagnosis. The potential of ALA-induced PpIX as a fluorescent theranostic agent is, however, yet to be fully fulfilled. In this review, we would like to describe the heme biosynthesis pathway in which PpIX is produced from ALA and its derivatives, summarize current clinical applications of ALA-based drugs, and discuss strategies for enhancing ALA-induced PpIX fluorescence and PDT response. Our goal is two-fold: to highlight the successes of ALA-based drugs in clinical practice, and to stimulate the multidisciplinary collaboration that has brought the current success and will continue to usher in more landmark advances.
Overview
CoChat Summary
## TL;DR
This review explains how 5-aminolevulinic acid (ALA) is converted to protoporphyrin IX (PpIX), and how that PpIX enables both fluorescence-guided tumor diagnosis and photodynamic therapy (PDT). It argues that ALA-based drugs are already highly successful in actinic keratosis, basal cell carcinoma, bladder cancer, and high-grade gliomas, while additional protocol, device, and pathway-targeting refinements may further improve outcomes.
## Key findings
- Five ALA-based drugs had received worldwide approval by the time of the review, and the paper identifies ALA-based therapy as “the most successful drug discovery and development endeavor in PDT and photodiagnosis.”
- For high-grade glioma, the paper reports that a randomized phase III trial found fluorescence-guided resection achieved more gross total resection than white-light surgery: 65% vs 36%, with higher 6-month progression-free survival (41% vs 21%).
- For bladder cancer, the paper reports that in 68 patients, ALA-induced fluorescence had 100% sensitivity and 68.5% specificity for tumor detection, and that fluorescence cystoscopy revealed 26 cancerous or precancerous lesions out of 299 biopsies that white light would have missed.
- For actinic keratosis and superficial BCC, the paper reports multiple clinical results, including 72% complete response at 12 weeks for head actinic keratosis with ALA + blue light, up to 91% complete response for AK and 97% for BCC with MAL-PDT, and about 85% lesion clearance with BF-200 ALA and a simulated daylight system.
- The review highlights enhancement strategies that can raise PpIX fluorescence or PDT response, including optimizing dose/timing, fractionated illumination, daylight or simulated daylight systems, iron chelation, FECH inhibition, ABCG2 inhibition, pro-survival pathway inhibition, and immune checkpoint blockade.
## Methods
- Narrative review of the ALA/PpIX heme biosynthesis pathway, therapeutic PDT mechanisms, intraoperative fluorescence imaging, and strategies to enhance ALA-PpIX fluorescence and ALA-PDT response.
- Uses published clinical trials, randomized trials, multicenter studies, and preclinical cell/animal studies as the evidence base; no new original patient cohort is reported in the paper.
- Main analysis is qualitative synthesis, organizing findings by mechanism and application area (actinic keratosis, BCC, bladder cancer, glioma), and comparing protocols, devices, and combination strategies.
## Limitations
- The paper states that the potential of ALA-induced PpIX as a fluorescent theranostic agent is “yet to be fully fulfilled.”
- It explicitly notes that whether targeting PpIX bioconversion and efflux will produce clinical benefit “remains to be seen,” and that clinical trials are needed to test whether combined fluorescence-guided surgery plus PDT improves survival beyond current standard practice.
- Evident from the text: much of the enhancement evidence comes from in vitro or animal studies, and several proposed inhibitors or protocol refinements are not yet clinically validated or are not available for clinical use.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
49 Valid · 5 Not valid · 87 Not checked · 18 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Probe-based sectioning microscopes with red light illumination are able to provide high-resolution quantitative imaging of PpIX even in deep tissues [81].”
§ 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy > 6. Strategies for Enhancing ALA-PpIX Fluorescence and ALA-PDT Response > 6.2. Device Improvements & Developments
What the sources say
- Disputedcites [81] Wei, 2019, Visualization Technologies for 5-ALA-Based Fluorescence-Guided Surgeries, J. Neurooncol. sourceExperimental — accuracy not yet measured
The Deep-tissue imaging techniques section (page not provided) says high-resolution imaging is typically limited to about 100 microns of tissue depth. It attributes quantitative PpIX imaging several millimeters deep with red-light excitation to wide-field systems with about 1 mm spatial resolution, not to high-resolution probe-based sectioning microscopes. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Photoactivation of endogenous PpIX induced by ALA results in the elimination of erythroleukemia cells as Malik et al. showed in 1987, which is the first report of using ALA-PDT for cell inactivation [5].”
§ 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy > 3. ALA as a Therapeutic Agent for PDT
What the sources say
- Partly supportedcites [5] Malik, 1987, Destruction of Erythroleukaemic Cells by Photoactivation of Endogenous Porphyrins, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Summary (p. 589) reports that ALA-treated Friend erythroleukaemia cells accumulated protoporphyrin and that irradiation disintegrated more than 95% of cells. The Discussion also reports photoinactivation, but says both uroporphyrin and protoporphyrin may act as photosensitizers; our copy does not establish the citing sentence’s additional claim that this was the first report of ALA-PDT for cell inactivation. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As a porphyrin precursor, ALA is metabolized in the heme biosynthetic pathway to produce protoporphyrin IX (PpIX), a fluorophore and photosensitizing agent.”
§ 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy > Abstract
What the sources say
- Supportedcites [8] Ajioka, 2006, Biosynthesis of Heme in Mammals, Biochim. Biophys. Acta (BBA)-Mol. Cell Res. source
Section 1.1 describes ALA entering the heme biosynthetic pathway, and section 1.3 identifies protoporphyrin IX as a later product with fluorescent properties. The Introduction attributes porphyria-related photosensitivity to fluorescent porphyrins, supporting the description of PpIX as a photosensitizing agent. The supplied passages have no page numbers. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Heme biosynthesis ends in the mitochondrial matrix where ferrous iron (Fe2+) is inserted into the tetrapyrrole core of PpIX by ferrochelatase (FECH) to form heme [8].”
§ 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy > 2. ALA-Mediated PpIX Biosynthesis in the Heme Biosynthesis Pathway
What the sources say
- Supportedcites [8] Ajioka, 2006, Biosynthesis of Heme in Mammals, Biochim. Biophys. Acta (BBA)-Mol. Cell Res. source
The Introduction (page not provided) states that ferrochelatase resides in the mitochondrial matrix and catalyzes insertion of ferrous iron into the tetrapyrrole macrocycle of protoporphyrin IX to generate heme. Section 1.4 (page not provided) identifies this as the final step of heme biosynthesis. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The finding that enhanced PpIX biosynthesis can be induced by exogenously applied ALA in tumor cells has led to the use of ALA as a prodrug for PpIX-mediated photodynamic therapy (PDT) and photodiagnosis [5,6].”
§ 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy > 1. Introduction
What the sources say
- Supportedcites [5] Malik, 1987, Destruction of Erythroleukaemic Cells by Photoactivation of Endogenous Porphyrins, Br. J. Cancer source
The Summary (p. 589) reports that adding 5-ALA induced porphyrin biosynthesis in Friend erythroleukaemic cells, with protoporphyrin accumulating after eight days. This supports the claim that exogenous ALA can enhance PpIX production in tumor cells; the experiment itself was limited to that cell line. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [6] Kennedy, 1990, Photodynamic Therapy with Endogenous Protoporphyrin: IX: Basic Principles and Present Clinical Experience, J. Photochem. Photobiol. B Biol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
94 more claims · 29 with their cited sources checked
Create a free account to see all 159 claims and to verify the 29 references still open.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 56
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145 · cited 1×
“As a non-invasive therapeutic modality, PDT with various photosensitizers has been used in clinical settings for both cancerous and non-cancerous diseases [14].”
BackgroundStummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Photodynamic therapy with endogenous protoporphyrin
Kennedy, J. C., Pottier, R. H., & Pross, D. C. (1990) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(90)85083-9 · Cited by 1,509 · cited 20×
“Their pioneering work of applying ALA topically for stimulating local PpIX production followed by aimed Bioengineering 2023, 10, 496 5 of 23 light illumination for cell inactivation marked the beginning of future successes of ALAPDT for AK and superficial BCC, the most common precancerous and cancerous skin lesions, r…”
BackgroundInfluentialTargeting Autophagy in Cancer: Recent Advances and Future Directions
Amaravadi, R. K., Kimmelman, A. C., & Debnath, J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0292 · Cited by 928
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202607599 · Cited by 822
Allen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 814
Walter, S., Susanne, S., Simon, W., Herbert, S., Clemens, F., Claudia, G., Alwin, E. G., Rainer, K., & Hans, J. R. (1998) · Neurosurgery · doi:10.1097/00006123-199803000-00017 · Cited by 690
Cited by
NIR-activated multifunctional agents for the combined application in cancer imaging and therapy
Repetowski, P., Warszyńska, M., & Dąbrowski, J. M. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103356 · Cited by 48
Enhancing 5-ALA-PDT efficacy against resistant tumor cells: Strategies and advances
Ebrahimi, S., Ghadiri, M. K., Stummer, W., & Gorji, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122808 · Cited by 39
Photosensitizers for Photodynamic Therapy of Brain Cancers—A Review
Bartusik‐Aebisher, D., Woźnicki, P., Dynarowicz, K., & Aebisher, D. (2023) · Brain Sciences · doi:10.3390/brainsci13091299 · Cited by 38
“Research was also undertaken on the combination of m -THPC with gold nanoparticles (AuNPs), and it was observed that under the influence of laser radiation of the PDT/PTT combination, phototoxicity was twice as high as compared to treatment with only PDT or only PTT [73].”
MethodChandratre, S., Olsen, J., Howley, R., & Chen, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115851 · Cited by 35
Self-citationDing, Q., Zhou, L., Xiong, T., Liu, J., Chen, L., Yoo, J., Xu, X., Jia, X., Chen, S., Chen, S., et al. (2025) · National Science Review · doi:10.1093/nsr/nwaf554 · Cited by 41
Godiyal, Y., Maheshwari, D., Taniguchi, H., Zinzuwadia, S. S., Díaz, Y. M., Tewari, D., & Bishayee, A. (2024) · Military Medical Research · doi:10.1186/s40779-024-00586-9 · Cited by 52
Current Photodynamic Therapy for Glioma Treatment: An Update
Aebisher, D., Przygórzewska, A., Myśliwiec, A., Dynarowicz, K., Krupka‐Olek, M., Bożek, A., Kawczyk‐Krupka, A., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12020375 · Cited by 26
“, effective doses, and mechanism of action The selection of an appropriate PS is one of the most important factors in achieving the intended The selection of an appropriate PS is one of the most important factors in achieving the intended e ff ect [103,121]. effect [103,121].”
BackgroundKazemi, K. S., Kazemi, P., Mivehchi, H., Nasiri, K., Hoseini, S. S. E., Nejati, S. T., Bahrami, P. P., Golestani, S., & Nabi‐Afjadi, M. (2024) · Biological Procedures Online · doi:10.1186/s12575-024-00252-3 · Cited by 31
Wang, X., Xu, X., Ma, Y., Tang, Y., & Huang, Z. W. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050686 · Cited by 21
“Its fluorescent and photodynamic properties offer unique theranostic tools for the examination and treatment of various precancerous and cancerous disorders [28,29].”
BackgroundYin, Q., Zhang, J., Zhang, H., Gao, J., Weng, L., Liu, T., Sun, S., Yao, Y., & Chen, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304639 · Cited by 21
Intraoperative fluorescence redefining neurosurgical precision
Regmi, M., Li, Y., Wang, Y., Liu, W., Dai, Y., Liu, S., Ma, K., Pan, L., Gan, J., Liu, H., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001847 · Cited by 15
Current and Emerging Fluorescence-Guided Techniques in Glioma to Enhance Resection
Nguyen, T. T. T., Mnatsakanyan, H., Yi, E. S., & Badr, C. E. (2025) · Cancers · doi:10.3390/cancers17162702 · Cited by 17
“This selective metabolic difference, combined with a disrupted BBB in high-grade gliomas and the loss of heme feedback regulation, promotes preferential uptake and retention of 5-ALA in tumor tissue [46] (Figure 1).”
Howley, R., Olsen, J., & Chen, B. (2024) · Photochemistry and Photobiology · doi:10.1111/php.13936 · Cited by 11
Self-citationLi, J., Huang, Y., Tao, J., Yang, H., & Zhu, H. (2025) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2025.104697 · Cited by 11
Chandratre, S., Merenich, D., Myers, K., & Chen, B. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02012-w · Cited by 10
Self-citationPhotodynamic therapy in glioma cell culture
Aebisher, D., Rogóż, K., Yakub, Z. A., Dynarowicz, K., Myśliwiec, A., Mytych, W., Komosińska‐Vassev, K., Misiołek, M., Kawczyk‐Krupka, A., & Bartusik‐Aebisher, D. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2024-0407 · Cited by 5
Zhang, S., Xu, R., Golding, J. B., Deng, L., Zhou, J., Liang, L., & Wang, B. (2024) · Postharvest Biology and Technology · doi:10.1016/j.postharvbio.2024.113339 · Cited by 7
Nishimura, N., Miyake, M., Onishi, S., Tomizawa, M., Shimizu, T., Onishi, K., Hori, S., Morizawa, Y., Gotoh, D., Nakai, Y., et al. (2024) · Cancers · doi:10.3390/cancers16234112 · Cited by 3
Inglot, J., Bartusik‐Aebisher, D., Myśliwiec, A., Dynarowicz, K., Paul, A., Xavierselvan, M., & Aebisher, D. (2026) · Biomedicines · doi:10.3390/biomedicines14061314 · Cited by 4
“Therefore, results obtained in breast cancer, ovarian cancer, prostate cancer, and several gastrointestinal tumors should be interpreted with caution until confirmed in larger clinical trials [10,50,51,77,79,88,89,96,101,105–108].”
InfluentialOlsen, J., Chandratre, S., Alsalamah, L., Merenich, D., Myers, K. A., & Chen, B. (2025) · Photochemistry and Photobiology · doi:10.1111/php.70057 · Cited by 2
“1 Particularly, targeting the intrinsic PpIX-reducing mechanisms in tumor cells such as PpIX to heme bioconversion and PpIX efflux via ABCG2 has shown promising results of therapeutic enhancement.”
Self-citationChandratre, S., Olsen, J., & Chen, B. (2025) · Photochemistry and Photobiology · doi:10.1111/php.14077 · Cited by 1
Self-citationIshikawa, S., Kawasaki, K., Yano, K., Kazumura, K., Tsukahara, T., Taniguchi, S., Miura, H., & Inoue, R. (2026) · Veterinary World · doi:10.14202/vetworld.2026.355-365 · Cited by 1
“Five-aminolevulinic acid (5-ALA) is a naturally occurring amino acid and a precursor of protoporphyrin IX, the fundamental building block of heme [1].”
Güler, S. İ., Demircioglu, E. E., Yıldırım, S., Abdallah, S. O., Eroğlu, E., & Erdem, S. S. (2026) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2026.113490
Goldschmidt, S. L., Marcu, L., Ehrlich, K., Hassan, M. A., Rivas, I., Birkeland, A. C., Zhou, X., Bec, J., García, A. A., Chen, S., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-37001-3
“Similar to other studies evaluating the clinical utility of 5-ALA, there was a high sensitivity but moderate specificity in the ability to identify neoplastic tissue based on visual fluorescence to the naked eye 12,26,32–34 .”
Effects of ABCG2 knockdown on therapeutic enhancement of 5‐aminolevulinic acid with lapatinib
Wescoat, J., Cabral, C., & Chen, B. (2026) · Photochemistry and Photobiology · doi:10.1111/php.70157
Self-citationLiposomal Salvianolic Acid B Enhances ALA-PDT in Oral Leucoplakia via ROS and AKT/mTOR Signalling
(40767), Y. Z., Zhao, X., Han, X., Shen, X., Huang, R., Liu, W., & Wu, L. (2026) · International Dental Journal · doi:10.1016/j.identj.2026.109634
Sanders, H. S., Rooney, K. A., Panethiere, M. A., Atkinson, K. M., & Smith, B. D. (2026) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-026-00944-7
“Many carboxylic ester derivatives of 5-ALA have been tested and two of them are clinically approved, namely, the methyl ester for topical treatment of actinic keratosis and basal cell carcinoma and the hexyl ester for blue-light cystoscopy detection of bladder cancer [16].”
Gregoriis, L. D., Dotta, T. C., Petrini, M., Lodovico, S. D., D’Ercole, L., D’Ercole, S., & Tripodi, D. (2025) · Applied Sciences · doi:10.3390/app15126491 · Cited by 1
Fluorescence-Enhanced Assessments for Human Breast Cancer Cell Characterizations
Ghezelbash, M., Sajad, B., & Hojatizadeh, S. (2024) · Photonics · doi:10.3390/photonics11080746
Metadata
- Authors
- Howley, R., Chandratre, S., & Chen, B.
- Affiliations
- Saint Joseph's University (US)
- Corresponding author
- Chen, Bin
- ORCID
- Howley, Richard
- Venue
- Bioengineering
- Publisher
- MDPI AG
- Published
- 2023-04-21
- Volume
- 10
- Issue
- 4
- Pages
- 496
- ISSN
- 2306-5354 (ISSN-L)
- PMC
- PMC10136048
- OpenAlex
- W4366775638
- Cited by
- 33
- References
- 180
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 15 · 2023: 3
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Bioengineering (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NIH (R15CA268200)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Materials Chemistry › Porphyrin and Phthalocyanine Chemistry
- Keywords
- 5-aminolevulinic acid, protoporphyrin IX, heme biosynthesis, photodynamic therapy, theranostics, photosensitizers, actinic keratosis, basal cell carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.